MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody® Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis
ZUG, Switzerland, May 6, 2021 /PRNewswire/ -- MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced that full results of a Phase 2b study of its Tri-specific Nanobody® Sonelokimab were published in The Lancet. Sonelokimab is